Martin Pflügler PhD, MBA

Martin Pflügler studied pharmacy and pharmaceutical science at the Ludwig-Maximilian University Munich (2004 to 2012).

After his master thesis at Roche dealing with antibodies, he joined Synimmune GmbH, a spin-off company of the Department of Immunology at the University of Tübingen, as a PhD candidate and, besides building up the quality control unit, developed new bispecific antibody constructs (2012-2015).

After obtaining his PhD he was engaged in discovery, development, and production of bispecific antibodies as postdoc in the lab of Gundram Jung (2015- 2018). From 2017 to 2023, he served as GMP manager of the Clinical Cooperation Unit Translational Immunology within the German Cancer Consortium (DKTK) at DKFZ headed by Helmut Salih, where, in addition to his development activities, he supervised GMP production of several bispecific antibodies for clinical use.

2020 he earned an MBA in international management at the European School of Business Administration at Reutlingen University.

Martin Pfluegler is inventor on several patents describing novel bispecific constructs and other clinical candidates for immunotherapy of cancer.

In 2023 he founded TWYCE GmbH together with Gundram Jung and Helmut Salih and serves as CEO.